-
Je něco špatně v tomto záznamu ?
High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma
A. Giubellino, U. Shankavaram, P. Bullova, J. Schovanek, Y. Zhang, M. Shen, N. Patel, A. Elkahloun, MJ. Lee, J. Trepel, M. Ferrer, K. Pacak,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Intramural
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- dospělí MeSH
- feochromocytom farmakoterapie genetika sekundární MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidé MeSH
- messenger RNA genetika MeSH
- myši MeSH
- nádorové biomarkery genetika metabolismus MeSH
- nádory nadledvin farmakoterapie genetika patologie MeSH
- objevování léků * MeSH
- paragangliom farmakoterapie genetika patologie MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- přehodnocení terapeutických indikací léčivého přípravku * MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky farmakologie MeSH
- průtoková cytometrie MeSH
- rychlé screeningové testy * MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
- signální transdukce MeSH
- stanovení celkové genové exprese MeSH
- western blotting MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Research Support, N.I.H., Intramural MeSH
Drug repurposing or repositioning is an important part of drug discovery that has been growing in the last few years for the development of therapeutic options in oncology. We applied this paradigm in a screening of a library of about 3,800 compounds (including FDA-approved drugs and pharmacologically active compounds) employing a model of metastatic pheochromocytoma, the most common tumor of the adrenal medulla in children and adults. The collection of approved drugs was screened in quantitative mode, testing the compounds in compound-titration series (dose-response curves). Analysis of the dose-response screening data facilitated the selection of 50 molecules with potential bioactivity in pheochromocytoma cells. These drugs were classified based on molecular/cellular targets and signaling pathways affected, and selected drugs were further validated in a proliferation assay and by flow cytometric cell death analysis. Using meta-analysis information from molecular targets of the top drugs identified by our screening with gene expression data from human and murine microarrays, we identified potential drugs to be used as single drugs or in combination. An example of a combination with a synergistic effect is presented. Our study exemplifies a promising model to identify potential drugs from a group of clinically approved compounds that can more rapidly be implemented into clinical trials in patients with metastatic pheochromocytoma or paraganglioma.
Medical Oncology Branch National Cancer Institute NIH Bethesda Maryland United States of America
National Center for Advancing Translational Sciences NIH Rockville Maryland United States of America
National Human Genome Research Institute NIH Bethesda Maryland United States of America
Radiation Oncology Branch National Cancer Institute NIH Bethesda Maryland United States of America
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014429
- 003
- CZ-PrNML
- 005
- 20150421092155.0
- 007
- ta
- 008
- 150420s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0090458 $2 doi
- 035 __
- $a (PubMed)24699253
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Giubellino, Alessio $u Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, Bethesda, Maryland, United States of America.
- 245 10
- $a High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma / $c A. Giubellino, U. Shankavaram, P. Bullova, J. Schovanek, Y. Zhang, M. Shen, N. Patel, A. Elkahloun, MJ. Lee, J. Trepel, M. Ferrer, K. Pacak,
- 520 9_
- $a Drug repurposing or repositioning is an important part of drug discovery that has been growing in the last few years for the development of therapeutic options in oncology. We applied this paradigm in a screening of a library of about 3,800 compounds (including FDA-approved drugs and pharmacologically active compounds) employing a model of metastatic pheochromocytoma, the most common tumor of the adrenal medulla in children and adults. The collection of approved drugs was screened in quantitative mode, testing the compounds in compound-titration series (dose-response curves). Analysis of the dose-response screening data facilitated the selection of 50 molecules with potential bioactivity in pheochromocytoma cells. These drugs were classified based on molecular/cellular targets and signaling pathways affected, and selected drugs were further validated in a proliferation assay and by flow cytometric cell death analysis. Using meta-analysis information from molecular targets of the top drugs identified by our screening with gene expression data from human and murine microarrays, we identified potential drugs to be used as single drugs or in combination. An example of a combination with a synergistic effect is presented. Our study exemplifies a promising model to identify potential drugs from a group of clinically approved compounds that can more rapidly be implemented into clinical trials in patients with metastatic pheochromocytoma or paraganglioma.
- 650 _2
- $a nádory nadledvin $x farmakoterapie $x genetika $x patologie $7 D000310
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 12
- $a objevování léků $7 D055808
- 650 12
- $a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 12
- $a rychlé screeningové testy $7 D057166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
- 650 _2
- $a paragangliom $x farmakoterapie $x genetika $x patologie $7 D010235
- 650 _2
- $a feochromocytom $x farmakoterapie $x genetika $x sekundární $7 D010673
- 650 _2
- $a messenger RNA $x genetika $7 D012333
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a nádorové biomarkery $x genetika $x metabolismus $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 700 1_
- $a Shankavaram, Uma $u Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, United States of America.
- 700 1_
- $a Bullova, Petra $u Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, Bethesda, Maryland, United States of America; Department of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 700 1_
- $a Schovanek, Jan $u Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, Bethesda, Maryland, United States of America; Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital of Olomouc, Czech Republic.
- 700 1_
- $a Zhang, Yaqin $u National Center for Advancing Translational Sciences, NIH, Rockville, Maryland, United States of America.
- 700 1_
- $a Shen, Min $u National Center for Advancing Translational Sciences, NIH, Rockville, Maryland, United States of America.
- 700 1_
- $a Patel, Nikita $u Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, Bethesda, Maryland, United States of America.
- 700 1_
- $a Elkahloun, Abdel $u National Human Genome Research Institute, NIH, Bethesda, Maryland, United States of America.
- 700 1_
- $a Lee, Min-Jung $u Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, United States of America.
- 700 1_
- $a Trepel, Jane $u Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, United States of America.
- 700 1_
- $a Ferrer, Marc $u National Center for Advancing Translational Sciences, NIH, Rockville, Maryland, United States of America.
- 700 1_
- $a Pacak, Karel $u Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, Bethesda, Maryland, United States of America.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 4 (2014), s. e90458
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24699253 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150421092453 $b ABA008
- 999 __
- $a ok $b bmc $g 1072010 $s 897307
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 4 $d e90458 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20150420